Sol-Gel Technologies Current Ratio 2016-2024 | SLGL
Sol-Gel Technologies current ratio from 2016 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Sol-Gel Technologies Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$0.04B |
$0.01B |
5.81 |
| 2024-06-30 |
$0.04B |
$0.01B |
7.36 |
| 2024-03-31 |
$0.04B |
$0.01B |
6.89 |
| 2023-12-31 |
$0.04B |
$0.01B |
9.10 |
| 2023-09-30 |
$0.05B |
$0.01B |
10.09 |
| 2023-06-30 |
$0.05B |
$0.01B |
9.10 |
| 2023-03-31 |
$0.04B |
$0.00B |
10.37 |
| 2022-12-31 |
$0.04B |
$0.00B |
12.93 |
| 2022-09-30 |
$0.05B |
$0.00B |
18.31 |
| 2022-06-30 |
$0.05B |
$0.00B |
15.03 |
| 2022-03-31 |
$0.05B |
$0.00B |
11.09 |
| 2021-12-31 |
$0.06B |
$0.01B |
4.88 |
| 2021-09-30 |
$0.05B |
$0.01B |
5.05 |
| 2021-06-30 |
$0.04B |
$0.01B |
8.03 |
| 2021-03-31 |
$0.05B |
$0.00B |
10.83 |
| 2020-12-31 |
$0.05B |
$0.01B |
8.95 |
| 2020-09-30 |
$0.06B |
$0.01B |
8.55 |
| 2020-06-30 |
$0.07B |
$0.01B |
9.94 |
| 2020-03-31 |
$0.07B |
$0.01B |
9.51 |
| 2019-12-31 |
$0.06B |
$0.01B |
8.58 |
| 2019-09-30 |
$0.06B |
$0.01B |
7.80 |
| 2019-06-30 |
$0.06B |
$0.01B |
8.00 |
| 2019-03-31 |
$0.06B |
$0.01B |
8.29 |
| 2018-12-31 |
$0.07B |
$0.01B |
13.48 |
| 2018-09-30 |
$0.08B |
$0.01B |
15.96 |
| 2018-06-30 |
$0.08B |
$0.00B |
20.77 |
| 2018-03-31 |
$0.09B |
$0.00B |
43.22 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.02B |
$0.07B |
0.25 |
| 2017-06-30 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.01B |
$0.04B |
0.20 |
| 2015-12-31 |
$0.01B |
$0.02B |
0.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
